X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Sanofi will acquire all the assets and liabilities associated with INBRX-101, an optimized, recombinant alpha-1 antitrypsin augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency.
Lead Product(s): INBRX-101
Therapeutic Area: Genetic Disease Product Name: INBRX-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $2,196.0 million Upfront Cash: $2,196.0 million
Deal Type: Acquisition January 22, 2024
Details:
Under the agreement, all non-101 assets and liabilities, including INBRX-105, INBRX-106, INBRX-109, Inhibrx's non-101 discovery pipeline and its corporate infrastructure, will be spun out from the Company into a new publicly traded company, Inhibrx Biosciences.
Lead Product(s): INBRX-105,Pembrolizumab
Therapeutic Area: Oncology Product Name: INBRX-105
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $200.0 million Upfront Cash: $200.0 million
Deal Type: Demerger January 22, 2024
Details:
INBRX-109 is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation, which is investigated for Ewing sarcoma.
Lead Product(s): INBRX-109,Temozolomide,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: INBRX-109
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
INBRX-101 is a precisely engineered recombinant human AAT-Fc fusion protein designed to safely achieve and maintain levels of Alpha-1 Antitrypsin Deficiency and received Fast Track Designation.
Lead Product(s): INBRX-101
Therapeutic Area: Genetic Disease Product Name: INBRX-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023
Details:
INBRX-101 is a precisely engineered recombinant human AAT-Fc fusion protein designed to safely achieve and maintain levels of alpha-1 antitrypsin (AAT) in patients with emphysema due to alpha-1 antitrypsin deficiency (AATD).
Lead Product(s): rhAAT-Fc
Therapeutic Area: Genetic Disease Product Name: INBRX-101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2023
Details:
Under this agreement with Inhibrx, NorthStar will support the development of a prespecified number of Inhibrx’s novel biologic products by providing the Ac-225 supply for the Actinium-225 Conjugated Therapy and access to its integrated radiopharmaceutical CDMO services.
Lead Product(s): Actinium-225 Conjugated Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: NorthStar Medical Radioisotopes
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 04, 2023
Details:
INBRX-109 is a precision-engineered, tetravalent DR5 agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation being developed for the treatment of patients with unresectable or metastatic conventional chondrosarcoma and chondrosarcoma.
Lead Product(s): INBRX-109
Therapeutic Area: Oncology Product Name: INBRX-109
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2022
Details:
INBRX-101 is precisely engineered recombinant human AAT-Fc fusion protein designed to safely achieve and maintain levels of alpha-1 antitrypsin found in healthy individuals with dosing interval compared to weekly infusion interval plasma-derived AAT therapies.
Lead Product(s): rhAAT-Fc
Therapeutic Area: Genetic Disease Product Name: INBRX-101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
Details:
INBRX-101 (rhAAT-Fc) is precisely engineered fusion protein designed to safely achieve and maintain levels of alpha-1 antitrypsin, or AAT, found healthy individuals with less frequent dosing interval compared weekly infusion interval of available plasma-derived AAT therapies.
Lead Product(s): rhAAT-Fc
Therapeutic Area: Genetic Disease Product Name: INBRX-101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
Details:
INBRX-109 is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation.
Lead Product(s): INBRX-109
Therapeutic Area: Oncology Product Name: INBRX-109
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
